Cardiovascular Events According to Inhaler Therapy and Comorbidities in Chronic Obstructive Pulmonary Disease

References

• Agustí A, Hogg JC. Update on the pathogenesis of chronic obstructive pulmonary disease. N Engl J Med. 2019;381(13):1248–1256. doi:10.1056/NEJMra1900475
   PubMed Web of Science ®Google Scholar
• Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007;370(9589):765–773. doi:10.1016/S0140-6736(07)61380-4
   PubMed Web of Science ®Google Scholar
• Divo M, Cote C, de Torres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(2):155–161. doi:10.1164/rccm.201201-0034OC
   PubMed Web of Science ®Google Scholar
• Müllerova H, Agusti A, Erqou S, Mapel DW. Cardiovascular comorbidity in COPD: systematic literature review. Chest. 2013;144(4):1163–1178. doi:10.1378/chest.12-2847
   PubMed Web of Science ®Google Scholar
• Sidney S, Sorel M, Quesenberry CP Jr, DeLuise C, Lanes S, Eisner MD. COPD and incident cardiovascular disease hospitalizations and mortality: kaiser Permanente Medical Care Program. Chest. 2005;128(4):2068–2075. doi:10.1378/chest.128.4.2068
   PubMed Web of Science ®Google Scholar
• Huiart L, Ernst P, Suissa S. Cardiovascular morbidity and mortality in COPD. Chest. 2005;128(4):2640–2646. doi:10.1378/chest.128.4.2640
   PubMed Web of Science ®Google Scholar
• Singh S, Loke YK, Enright P, Furberg CD. Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications. Thorax. 2013;68(1):114–116. doi:10.1136/thoraxjnl-2011-201275
   PubMed Web of Science ®Google Scholar
• Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–789. doi:10.1056/NEJMoa063070
   PubMed Web of Science ®Google Scholar
• Singh D, Agusti A, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. Eur Respir J. 2019;53(5). doi:10.1183/13993003.00164-2019
   Web of Science ®Google Scholar
• Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. New Engl J Med. 2008;359(15):1543–1554. doi:10.1056/NEJMoa0805800
   PubMed Web of Science ®Google Scholar
• Koarai A, Yamada M, Ichikawa T, Fujino N, Kawayama T, Sugiura H. Triple versus LAMA/LABA combination therapy for patients with COPD: a systematic review and meta-analysis. Respir Res. 2021;22(1):183. doi:10.1186/s12931-021-01777-x
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnhart F, Brealey N, et al. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. New Engl J Med. 2018;378(18):1671–1680. doi:10.1056/NEJMoa1713901
   PubMed Web of Science ®Google Scholar
• Au DH, Lemaitre RN, Randall Curtis J, Smith NL, Psaty BM. The risk of myocardial infarction associated with inhaled β-adrenoceptor agonists. Am J Respir Crit Care Med. 2000;161(3):827–830. doi:10.1164/ajrccm.161.3.9904006
   PubMed Web of Science ®Google Scholar
• Gershon A, Croxford R, Calzavara A, et al. Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease. JAMA Intern Med. 2013;173(13):1175–1185. doi:10.1001/jamainternmed.2013.1016
   PubMed Web of Science ®Google Scholar
• Wang M-T, Liou J-T, Lin CW, et al. Association of cardiovascular risk with inhaled long-acting bronchodilators in patients with chronic obstructive pulmonary disease: a nested case-control study. JAMA Intern Med. 2018;178(2):229–238. doi:10.1001/jamainternmed.2017.7720
   PubMed Web of Science ®Google Scholar
• Wilchesky M, Ernst P, Brophy JM, Platt RW, Suissa S. Bronchodilator use and the risk of arrhythmia in COPD: part 1: Saskatchewan cohort study. Chest. 2012;142(2):298–304. doi:10.1378/chest.10-2499
   PubMed Web of Science ®Google Scholar
• Vestbo J, Anderson JA, Brook RD, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016;387(10030):1817–1826. doi:10.1016/S0140-6736(16)30069-1
   PubMed Web of Science ®Google Scholar
• Wilchesky M, Ernst P, Brophy JM, Platt RW, Suissa S. Bronchodilator use and the risk of arrhythmia in COPD: part 2: reassessment in the larger Quebec cohort. Chest. 2012;142(2):305–311. doi:10.1378/chest.11-1597
   PubMed Web of Science ®Google Scholar
• Kim J-A, Yoon S, Kim L-Y, Kim D-S. Towards actualizing the value potential of Korea Health Insurance Review and Assessment (HIRA) data as a resource for health research: strengths, limitations, applications, and strategies for optimal use of HIRA data. J Korean Med Sci. 2017;32(5):718–728. doi:10.3346/jkms.2017.32.5.718
   PubMed Web of Science ®Google Scholar
• Lee J, Lee JH, Kim J-A, Rhee CK. Trend of cost and utilization of COPD medication in Korea. Int J Chronic Obstr. 2017;12:27. doi:10.2147/COPD.S121687
   PubMed Web of Science ®Google Scholar
• Lee CH, Kim K, Hyun MK, Jang EJ, Lee NR, Yim JJ. Use of inhaled corticosteroids and the risk of tuberculosis. Thorax. 2013;68(12):1105–1113. doi:10.1136/thoraxjnl-2012-203175
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi:10.1016/0021-9681(87)90171-8
   PubMedGoogle Scholar
• Yang M, Li Y, Jiang Y, Guo S, He J-Q, Sin DD. Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Eur Respir J. 2022.
   Web of Science ®Google Scholar
• Singh S, Loke YK, Enright PL, Furberg CD. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ. 2011;342.
   Google Scholar
• Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008;300(12):1439–1450. doi:10.1001/jama.300.12.1439
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. New Engl J Med. 2016;374(23):2222–2234. doi:10.1056/NEJMoa1516385
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnacle H, Birk R, et al. FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;196(4):438–446. doi:10.1164/rccm.201703-0449OC
   PubMed Web of Science ®Google Scholar
• Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391(10125):1076–1084. doi:10.1016/S0140-6736(18)30206-X
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell’Aniello S, Ernst P. Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events. Eur Respir J. 2017;49(5):1602245. doi:10.1183/13993003.02245-2016
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Zhong N, Ichinose M, et al. Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study. Int J Chronic Obstr. 2017;12:339. doi:10.2147/COPD.S125058
   PubMed Web of Science ®Google Scholar
• Scichilone N, Basile M, Battaglia S, Bellia V. What proportion of chronic obstructive pulmonary disease outpatients is eligible for inclusion in randomized clinical trials? Respiration. 2014;87(1):11–17. doi:10.1159/000355082
   PubMed Web of Science ®Google Scholar
• Suissa S, Ernst P, Vandemheen KL, Aaron S. Methodological issues in therapeutic trials of COPD. Eur Respir J. 2008;31(5):927–933. doi:10.1183/09031936.00098307
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of β-agonists in patients with asthma and COPD: a meta-analysis. Chest. 2004;125(6):2309–2321. doi:10.1378/chest.125.6.2309
   PubMed Web of Science ®Google Scholar
• Wang H, Lu Y, Wang Z. Function of cardiac M3 receptors. Auton. Autacoid Pharmacol. 2007;27(1):1–11. doi:10.1111/j.1474-8673.2006.00381.x
   PubMedGoogle Scholar
• Kistemaker LE, Bos IS, Hylkema MN, et al. Muscarinic receptor subtype-specific effects on cigarette smoke-induced inflammation in mice. Europ resp J. 2013;42(6):1677–1688. doi:10.1183/09031936.00112412
   PubMed Web of Science ®Google Scholar
• Libby P. Inflammation in atherosclerosis. Arteriosclerosis Thrombosis Vasc Biol. 2012;32(9):2045–2051. doi:10.1161/ATVBAHA.108.179705
   PubMed Web of Science ®Google Scholar
• Sin DD, Man SP, Marciniuk DD, et al. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;177(11):1207–1214. doi:10.1164/rccm.200709-1356OC
   PubMed Web of Science ®Google Scholar
• Yakar HI, Gunen H, Pehlivan E, Aydogan S. The role of tuberculosis in COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:323–329. doi:10.2147/COPD.S116086
   PubMed Web of Science ®Google Scholar
• Guiot J, Henket M, Frix A-N, et al. Combined obstructive airflow limitation associated with interstitial lung diseases (O-ILD): the bad phenotype? Respir Res. 2022;23(1):1–9. doi:10.1186/s12931-022-02006-9
   PubMed Web of Science ®Google Scholar
• Jang S, Kim Y, Cho WK. A Systematic Review and Meta-Analysis of Telemonitoring Interventions on Severe COPD Exacerbations. Int J Environ Res Public Health. 2021;18(13). doi:10.3390/ijerph18136757
   Web of Science ®Google Scholar
• Goto T, Shimada YJ, Faridi MK, Camargo CA, Hasegawa K. Incidence of Acute Cardiovascular Event After Acute Exacerbation of COPD. J Gen Intern Med. 2018;33(9):1461–1468. doi:10.1007/s11606-018-4518-3
   PubMed Web of Science ®Google Scholar